Semaglutide vs Tirzepatide for Weight Loss in Adults - Deaths Update
Searching US FAERS is always useful before letting your doctor prescribe a drug that could kill you.
I will update every 3 months when FAERS provides more horror detail or new publications emerge.
US FAERS shows an explosion for Deaths and Adverse Events for Tirzepatide1 with 141 Dead from 30,229 case reports to 30 June 2024.
However that is just part of the Death Toll, because when I search tradenames I find Mounjaro yields 133 Deaths from 35,220 cases.
Zepbound yields 1 Death from 3,807 cases.
Similar pattern to Semaglutide with 454 Dead from 31,181 case reports to 30 June 2024.
Current Death count to 30 June 2024 for Ozempic is 301 Deaths from 21,638 cases.
Current Death count to 30 June 2024 for Wegovy is 41 Deaths from 4,418 cases.
Note these Deaths vary from numbers previously reported, so I wonder if any records have been deleted by FAERS?2
Discrepancies in FAERS Death Tolls might be to do with victims prescribed multiple drugs at the same time so will delve further.
Australian Deaths
To 29 July 2024, the TGA DAEN reports:
Mounjaro 1 Death from 19 reports where it was the only suspect.
Ozempic 17 Deaths from 431 reports where it was the only suspect.
Semaglutide unbranded 1 Death.
May 2025 Update
Tirzepatide does not decrease the Gut leakage increase of Endotoxin in rodents on a High Fat Diet (HFD) as reported in a Korean patent.3
Experimental Example 6: Analysis of the effect of Endotoxin and Liver damage treatment
If obesity is left untreated, it can progress to non-metabolic fatty liver disease (NAFLD) or metabolic syndrome-associated steatohepatitis (NASH) and even liver cirrhosis, which is an irreversible liver damage disease. Therefore, the inventors of the present invention investigated whether the present inventors could suppress the increase in metabolic endotoxemia (blood endotoxemia) and liver damage, which are symptoms that often occur in obese animal models.
After administering Tirzepatide mimetic, a GLP-1/GIPR dual agonist at the same efficacy concentration, and a dual specificity fusion protein (MG12) according to an embodiment of the present invention for 2 weeks, the serum was obtained and component analysis was performed.
For endotoxemia analysis, a mouse LPS ELISA kit (CSB-E13066m, Cusabio) was used for analysis, and for liver damage analysis, ALT levels were measured using dry-chem equipment (DRI-CHEM NX-500, FUJI).
As a result, as confirmed in Fig. 7a, it was confirmed that the amount of serum LPS (Endotoxin, Lipopolysaccharide) increased due to diet-induced obesity (DIO), which induced endotoxemia.
This value was not decreased when Tirzepatide mimetic was administered, but it was confirmed that it was decreased to the control level when the dual specificity fusion protein according to an embodiment of the present invention was administered.
In addition, as a result of analyzing the degree of liver damage, it was confirmed that the ALT level was significantly increased due to liver damage caused by diet-induced obesity, as confirmed in Fig. 7b.
In the Tirzepatide mimetic administration group, the ALT level was decreased to half that of the vehicle administration group, and in the case of the dual specificity fusion protein (MG12) administration group according to an embodiment of the present invention, it was confirmed that the ALT level reduction effect was improved to a statistically significant level compared to the Tirzepatide mimetic administration group.
FAERS Deaths Update
To 31 March 2025
Tirzepatide 298
Semaglutide 649
Mounjaro 267
Ozempic 441
Wegovy 60
Zepbound 16
https://en.wikipedia.org/wiki/Tirzepatide
Ozempic Semaglutide Deaths. Endotoxin Hits your Macrophages > Makes Exosomes > miR-155 Hits your Epithelial Progenitor Cells
TGA Australia produced a weird report on a Diabetes drug called Ozempic Semaglutide marketed in Australia by Novo Nordisk Pharmaceuticals Pty Ltd.
성영철, 양상인, 노재일. Seong Yeong-cheol, Yang Sang-in, Noh Jae-il. 21 June 2024. Novel bispecific fusion protein and use thereof. https://patents.google.com/patent/WO2024263005A1/en
It would be interesting to know the statistical breakup of the biological sex of the people who are using these weight-loss drugs, and the gender & age breakup of the death rates.
What I find really distasteful is that the amoral people who run these pharmaceutical corporations have no doubt identified women as a key susceptible market for their product – as has the ‘cosmetic surgery industry’. The pharmaceutical corporations are exploiting female insecurities about weight gain – insecurities that have been psychologically implanted by the wider cultural and media forces that impel women to feel that they must always ‘look attractive’ - no matter what.
I am astonished that the pharmaceutical industry and its local rent-seeker distribution base are just pressing ahead with impunity with the marketing of dangerous or suspect drugs. Either they have paid off their corporate media suppression agents bigly – or they simply have not understood that over the last four years the green curtain that previously masked their activities has been pulled ajar so that at least 20% of the population now understands that something is dangerously wrong with this appalling industry.
On top of this, the political establishment and their ‘health’ bureaucrat enablers continue to badly fail the Australian people.
Have you seen what the Common Law Court are achieving down under?
There is an alternative route to justice.
https://clciaustralia.com/